KANEKA (4118) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the cumulative Q3 period of the fiscal year ending March 2026, revenue and profit declined, with deteriorating profitability in the core business being the defining feature. Revenue was ¥598.28B (-0.8% YoY), Operating Income was ¥22.20B (-23.8%), and Ordinary Income was ¥19.26B (-26.1%). Meanwhile, Net Income attributable to owners of the parent increased to ¥18.44B (+4.0%), but this was driven by extraordinary income, including a ¥10.20B gain on the sale of investment securities, and does not indicate an improvement in operating earnings power. The decline in gross margin (27.7%→27.5%) coincided with an increase in SG&A expenses (+3.2%), causing the Operating Income margin to contract from 4.8% to 3.7%.

Factors Affecting Results

【Revenue】Revenue was ¥598.28B, down 0.8% YoY. By segment, the core Material Solutions Unit declined to ¥241.53B (-5.5% YoY), making it the primary cause of the revenue decline. In contrast, the Health Care Solutions Unit (¥57.32B, +3.4% YoY), Nutrition Solutions Unit (¥153.29B, +4.2% YoY), and Quality of Life Solutions Unit (¥145.37B, +0.8% YoY) all secured revenue growth.

【Profit and Loss】Operating Income was ¥22.20B (-23.8% YoY). While the gross margin declined to 27.5% (27.7% in the previous year), SG&A expenses increased to ¥142.38B (+3.2% YoY), reducing cost absorption capacity. By segment, Material Solutions posted a significant decline in profit to ¥17.78B (-21.8% YoY), while Nutrition Solutions also recorded lower profit of ¥9.48B (-6.5% YoY) despite higher revenue. Ordinary Income declined further from Operating Income to ¥19.26B (-26.1% YoY), as interest expenses of ¥3.02B exceeded dividend income of ¥1.84B. Net Income was ¥18.44B (+4.0% YoY), supported mainly by net extraordinary income of ¥8.88B, including a ¥10.20B gain on the sale of investment securities. Overall, the company recorded lower revenue and profit, and the increase in Net Income was attributable to temporary factors.

Segment Analysis

Of the four reportable segments, only the Health Care Solutions Unit achieved both revenue and profit growth (revenue of ¥57.32B, +3.4% YoY; profit of ¥9.57B, +9.7% YoY), maintaining the highest margin in the company at 16.7%. The Material Solutions Unit recorded lower revenue of ¥241.53B (-5.5% YoY) and profit of ¥17.78B (-21.8% YoY), making it the primary cause of the decline in company-wide profit. The Quality of Life Solutions Unit recorded higher revenue (¥145.37B, +0.8% YoY) but lower profit of ¥14.26B (-9.2% YoY). The Nutrition Solutions Unit also recorded higher revenue (¥153.29B, +4.2% YoY) but lower profit of ¥9.48B (-6.5% YoY). Against total reportable segment profit of ¥51.08B, company-wide expenses of ¥29.31B, primarily basic research and development expenses, were recognized, compressing consolidated Operating Income to ¥22.20B.

Key Financial Indicators

【Profitability】The Operating Income margin of 3.7% declined by approximately 1.1pt from 4.8% in the same period of the previous year. The Net Income margin improved slightly YoY to 3.1%, but was significantly affected by extraordinary income. Annualized ROE was 5.2% on a consolidated basis, with the low Net Income margin being the primary factor, in combination with an asset turnover ratio of 0.84x and financial leverage of 1.89x.【Cash Flow Quality】Accounts receivable of ¥180.79B and inventories of ¥118.47B together amount to approximately 50% of revenue, and the lengthening of DSO and DIO is an issue for capital efficiency.【Investment Efficiency】ROIC is approximately 3.1%, below the cost of capital. Under the capital-intensive structure involving property, plant and equipment of ¥353.29B (37.1% of total assets), there is room to improve the efficiency of invested capital.【Financial Soundness】The Equity Ratio is 52.9%, the D/E ratio is 0.89x, and the current ratio is 146.3%, indicating a relatively conservative capital structure. However, short-term borrowings of ¥142.98B account for the majority of interest-bearing debt, resulting in a high degree of dependence on short-term liabilities.

Cash Flow Analysis

Although direct data from the statement of cash flows is unavailable, funding trends can be assessed from changes in the balance sheet. Cash and deposits increased to ¥47.04B from ¥45.64B in the same period of the previous year, while short-term borrowings increased to ¥142.98B (¥132.51B in the previous year), indicating a growing tendency to rely on short-term borrowings for financing. Accounts receivable increased to ¥180.79B (+2.3% YoY), and inventories increased to ¥118.47B (+13.7% YoY). The accumulation of working capital amid declining revenue is a factor weighing on cash-generation capacity. Property, plant and equipment expanded to ¥353.29B (+3.8% YoY), indicating continued capital investment. The cash/short-term liabilities ratio remained at only 0.33x, meaning that short-term debt cannot be fully covered by cash on hand alone; liquidity management depends to some extent on refinancing and the smooth conversion of assets into cash.

Quality of Earnings

Against Operating Income of ¥22.20B, extraordinary income was centered on a ¥10.20B gain on the sale of investment securities. After deducting extraordinary losses of ¥1.32B, net extraordinary income contributed ¥8.88B to profit. The ¥18.44B Net Income attributable to owners of the parent was supported by this non-recurring factor and does not signify an improvement in operating earnings power. Non-operating income was ¥3.62B, equivalent to only 0.6% of revenue, and consisted mainly of dividend income of ¥1.84B and foreign exchange gains of ¥0.70B. Meanwhile, non-operating expenses of ¥6.56B included interest expenses of ¥3.02B, weighing on Ordinary Income. The gap between Ordinary Income of ¥19.26B and Net Income attributable to owners of the parent of ¥18.44B was limited to 4.2%. However, Profit Before Tax of ¥28.14B significantly exceeded Ordinary Income due to the impact of extraordinary income, meaning that the quality of Net Income remains dependent on temporary factors.

Earnings Forecast and Guidance

Progress toward the full-year revenue forecast of ¥800.00B was 74.8%, in line with the standard 75% level. However, progress toward the full-year Operating Income forecast of ¥34.00B was 65.3%, 9.7pt below the standard level. Progress toward the full-year Ordinary Income forecast of ¥28.30B was 68.0% (7.0pt below the standard level), while progress toward the full-year Net Income attributable to owners of the parent forecast of ¥31.50B was 58.5% (16.5pt below the standard level). Profit indicators are therefore progressing more slowly than revenue. Operating Income of ¥11.80B and Net Income attributable to owners of the parent of ¥13.06B are required in Q4, making the degree of recovery in the core business and trends in extraordinary income and expenses and the tax burden key to achieving the full-year forecasts.

Shareholder Returns

The Q2 dividend was ¥80.00 per share, and the full-year dividend forecast is ¥160.00. Based on the interim dividend payment of approximately ¥5.28B, the Payout Ratio against cumulative Q3 Net Income attributable to owners of the parent of ¥18.44B is approximately 28.6%. The forecast Payout Ratio calculated from forecast full-year EPS of ¥511.80 and the full-year dividend forecast of ¥160.00 is approximately 31.3%, indicating that the dividend burden is within a restrained range relative to the level of profit. Treasury shares increased by ¥8.75B YoY (¥11.73B→¥20.47B), confirming capital returns in addition to dividends. As the full-year Net Income progress rate remains at 58.5%, realization of the year-end dividend depends on securing profit in Q4.

Risk Factors

1. Declining revenue and profit in the core business: The Material Solutions Unit posted revenue of ¥241.53B (-5.5% YoY) and segment profit of ¥17.78B (-21.8% YoY). Fluctuations in demand for materials and raw material and fuel costs will be key to the recovery of company-wide profit.

2. Dependence on short-term financing: Short-term borrowings of ¥142.98B account for the majority of interest-bearing debt, and the short-term liabilities ratio is high. Cash and deposits of ¥47.04B are below short-term liabilities, making continued refinancing and the smooth conversion of assets into cash prerequisites for liquidity management.

3. Lengthening working-capital cycle: Accounts receivable of ¥180.79B and inventories of ¥118.47B together reach approximately 50% of revenue. If improvements in collection and inventory efficiency are delayed, the risks of valuation losses and funds being tied up during demand fluctuations will increase.

Industry Benchmark (For Reference; Based on Our Analysis)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the Operating Income margin and Net Income margin are significantly below the industry median, placing the company in the lower tier of the industry in terms of profitability.

Growth and Capital Efficiency

Revenue growth is below the industry median, lagging peers that are on a growth trajectory.

※Source: Based on our analysis

Key Earnings Highlights

1. Although revenue remained broadly flat, Operating Income declined 23.8% YoY, making improvement in core-business profitability the most important earnings-related issue. The simultaneous decline in gross margin and increase in SG&A expenses are observed as structural pressure factors.

2. The 4.0% increase in Net Income attributable to owners of the parent was supported by the temporary factor of a ¥10.20B gain on the sale of investment securities and must be distinguished from recurring earnings power. The contrast between the Health Care Solutions Unit’s revenue and profit growth and the Material Solutions Unit’s revenue and profit decline indicates variation in performance across divisions.

3. Progress toward the full-year Operating Income and Net Income forecasts was 65.3% and 58.5%, respectively, below standard progress levels. The earnings structure requires a recovery in core-business profit in Q4.

Theoretical Share Price (Reference Value)

Sensitivity: ¥7,463–¥7,901 at Cost of Equity ±1%; ¥7,656–¥7,691 at ω±0.1.

Notes:

• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value Per Share.
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest-rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional where necessary.

---End of Report---